ATNM
Actinium Pharmaceuticals, Inc.
NYSE AmericanUSDEQUITY
Healthcare
DELAYED
Sell
-29/100
Last price
1.09
▼ 0.02 (1.80%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
1.12
Prev close
1.11
Day high
1.12
Day low
1.05
Volume
52.79K
Market cap
$34.27M
P/E (TTM)
3.30
52W range
0.74 – 1.74
Day trading desk
Gap from prior close
+0.90%
Prior close 1.11
VWAP
1.07
+1.64% from price
Relative volume
0.37×
Quiet session
Session range
6.67%
1.05 – 1.12
Position in range
57%
Mid range
ATR (14D)
0.07
6.22% of price
Prior day high
1.22
PDH
Prior day low
1.02
PDL
Bid / ask spread
—
Quote not published
Session volume
50.73K
Avg 138.51K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-2.68%
-4.3%
1M
-11.38%
-12.5%
3M
+12.37%
+9.3%
6M
-6.84%
-21.4%
YTD
-19.85%
-33.4%
1Y
-30.13%
-45.5%
3Y
-80.54%
-161.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ATNM open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
2.54M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 2, 26 | STEINHART RICHARD I Director |
STOCK | 62.80K | $0 | Direct |
| Sep 2, 26 | ALMENOFF JUNE SHERIE Director |
STOCK | 18.00K | $0 | Direct |
| Sep 2, 26 | SETH SANDESH Chief Executive Officer |
STOCK | 1.78M | $0 | Direct |
| Sep 2, 26 | NICHOLSON C DAVID Director |
STOCK | 62.80K | $0 | Direct |
| Sep 2, 26 | SHETTY AJIT S Director |
STOCK | 61.60K | $0 | Direct |
| Sep 2, 26 | CHELL JEFFREY W. Director |
STOCK | 61.60K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ALMENOFF JUNE SHERIE |
Director | 18.00K | Stock Award(Grant) |
CHELL JEFFREY W. |
Director | 61.60K | Stock Award(Grant) |
NICHOLSON C DAVID |
Director | 63.30K | Stock Award(Grant) |
SETH SANDESH |
Chief Executive Officer | 1.97M | Stock Award(Grant) |
SHETTY AJIT S |
Director | 62.36K | Stock Award(Grant) |
STEINHART RICHARD I |
Director | 63.12K | Stock Award(Grant) |
Fundamentals
Market cap$34.27M
Enterprise value$-232.01K
Revenue (TTM)$35.09M
Gross profit$35.09M
EBITDA$9.79M
Net income$11.31M
EPS (TTM)$0.33
Free cash flow$7.14M
Total cash$36.47M
Total debt$1.34M
Book value / share$0.96
Shares outstanding31.44M
Float31.26M
Short % of float2.26%
Dividend yield0.00%
Beta (5Y)0.27
Valuation & profitability ratios
Trailing P/E3.30
Forward P/E-2.08
PEG ratio—
Price / sales—
Price / book1.13
EV / revenue-0.01
EV / EBITDA-0.02
Gross margin100.00%
Operating margin78.76%
Profit margin32.23%
Return on equity45.86%
Return on assets11.58%
Debt / equity4.43
Current ratio4.08
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $90.00K | $0 | $81.00K | $1.03M | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $21.12M | $30.05M | $38.67M | $23.14M | -29.7% |
| Selling, general & admin | $15.21M | $12.08M | $13.33M | $12.00M | +26.0% |
| Total operating expense | $36.34M | $42.12M | $52.00M | $35.13M | -13.7% |
| Operating income | -$36.25M | -$42.12M | -$51.92M | -$34.10M | +13.9% |
| Net interest income | $2.36M | $3.88M | $3.10M | $1.09M | -39.1% |
| Pre-tax income | -$33.89M | -$38.24M | -$48.82M | -$33.02M | +11.4% |
| Net income | -$33.89M | -$38.24M | -$48.82M | -$33.02M | +11.4% |
| Net income to common | -$33.89M | -$38.24M | -$48.82M | -$33.02M | +11.4% |
| Basic EPS | -1.09 | -1.27 | -1.83 | -1.37 | +14.2% |
| Diluted EPS | -1.09 | -1.27 | -1.83 | -1.37 | +14.2% |
| EBIT | -$36.25M | -$42.12M | -$51.92M | -$34.10M | +13.9% |
| EBITDA | -$35.43M | -$41.31M | -$51.13M | -$33.41M | +14.2% |
| Basic shares | 31.20M | 30.07M | 26.60M | 24.14M | +3.7% |
| Diluted shares | 31.20M | 30.07M | 26.60M | 24.14M | +3.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $48.00M | $72.90M | $76.68M | $108.91M | -34.2% |
| Cash & short-term investments | $48.00M | $72.90M | $76.68M | $108.91M | -34.2% |
| Total current assets | $49.38M | $74.51M | $78.26M | $110.94M | -33.7% |
| Property, plant & equipment | $2.06M | $2.07M | $2.87M | $2.95M | -0.5% |
| Total assets | $51.77M | $76.90M | $81.44M | $114.19M | -32.7% |
| Total current liabilities | $7.97M | $8.15M | $8.49M | $10.63M | -2.2% |
| Total debt | $1.69M | $1.57M | $2.11M | $2.58M | +7.7% |
| Total liabilities | $43.94M | $44.14M | $45.07M | $47.71M | -0.5% |
| Retained earnings | -$409.71M | -$375.83M | -$337.58M | -$288.76M | -9.0% |
| Shareholder equity | $7.83M | $32.76M | $36.38M | $66.48M | -76.1% |
| Working capital | $41.41M | $66.36M | $69.77M | $100.31M | -37.6% |
| Net tangible assets | $7.83M | $32.76M | $36.38M | $66.48M | -76.1% |
| Shares issued | 31.20M | 31.20M | 27.63M | 25.67M | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$33.89M | -$38.24M | -$48.82M | -$33.02M | +11.4% |
| Depreciation & amortisation | $821.00K | $811.00K | $790.00K | $699.00K | +1.2% |
| Stock-based compensation | $9.19M | $5.29M | $3.84M | $2.79M | +73.7% |
| Change in working capital | -$704.00K | -$932.00K | -$3.15M | $38.17M | +24.5% |
| Operating cash flow | -$24.58M | -$33.07M | -$47.34M | $8.64M | +25.7% |
| Capital expenditure | -$104.00K | -$11.00K | -$153.00K | -$366.00K | -845.5% |
| Investing cash flow | -$104.00K | -$11.00K | -$153.00K | -$366.00K | -845.5% |
| Financing cash flow | -$217.00K | $29.32M | $14.87M | $23.11M | -100.7% |
| Free cash flow | -$24.68M | -$33.08M | -$47.49M | $8.28M | +25.4% |
| End cash position | $48.33M | $73.23M | $76.99M | $109.61M | -34.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $35.00M | $0 | $0 | $90.00K | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $5.38M | $4.20M | $4.30M | $4.25M | $4.88M | — | +28.0% |
| Selling, general & admin | $2.06M | $1.70M | $2.12M | $1.53M | $2.62M | — | +20.9% |
| Total operating expense | $7.43M | $5.90M | $6.41M | $5.78M | $7.50M | — | +26.0% |
| Operating income | $27.57M | -$5.90M | -$6.41M | -$5.69M | -$7.50M | — | +567.0% |
| Net interest income | $336.00K | $381.00K | $474.00K | $561.00K | $625.00K | — | -11.8% |
| Pre-tax income | $27.90M | -$5.52M | -$5.94M | -$5.13M | -$6.88M | — | +605.3% |
| Tax provision | $0 | — | — | — | $0 | — | — |
| Net income | $27.90M | -$5.52M | -$5.94M | -$5.13M | -$6.88M | — | +605.3% |
| Net income to common | $27.90M | -$5.52M | -$5.94M | -$5.13M | -$6.88M | — | +605.3% |
| Basic EPS | 0.89 | -0.18 | — | -0.16 | -0.22 | -0.51 | +594.4% |
| Diluted EPS | 0.89 | -0.18 | — | -0.16 | -0.22 | -0.51 | +594.4% |
| EBIT | $27.57M | -$5.90M | -$6.41M | -$5.69M | -$7.50M | — | +567.0% |
| EBITDA | $27.81M | -$5.68M | -$6.21M | -$5.49M | -$7.30M | — | +589.3% |
| Basic shares | 31.40M | 31.24M | — | 31.20M | 31.20M | 31.20M | +0.5% |
| Diluted shares | 31.41M | 31.24M | — | 31.20M | 31.20M | 31.20M | +0.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $36.47M | $42.13M | $48.00M | $53.39M | $59.93M | -13.4% |
| Cash & short-term investments | $36.47M | $42.13M | $48.00M | $53.39M | $59.93M | -13.4% |
| Total current assets | $37.74M | $43.26M | $49.38M | $54.37M | $61.03M | -12.8% |
| Property, plant & equipment | $2.08M | $1.84M | $2.06M | $1.45M | $1.66M | +12.9% |
| Total assets | $40.16M | $45.44M | $51.77M | $56.15M | $63.02M | -11.6% |
| Total current liabilities | $9.26M | $7.35M | $7.97M | $6.83M | $8.31M | +26.0% |
| Total debt | $1.34M | $1.52M | $1.69M | $1.14M | $1.29M | -11.7% |
| Total liabilities | $9.86M | $43.13M | $43.94M | $42.37M | $44.00M | -77.2% |
| Retained earnings | -$387.33M | -$415.24M | -$409.71M | -$403.77M | -$398.64M | +6.7% |
| Shareholder equity | $30.30M | $2.30M | $7.83M | $13.78M | $19.01M | +1,215.2% |
| Working capital | $28.48M | $35.91M | $41.41M | $47.53M | $52.72M | -20.7% |
| Net tangible assets | $30.30M | $2.30M | $7.83M | $13.78M | $19.01M | +1,215.2% |
| Shares issued | 31.37M | 31.37M | 31.20M | 31.20M | 31.20M | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $27.90M | -$5.52M | -$5.94M | -$5.13M | -$6.88M | +605.3% |
| Depreciation & amortisation | $241.00K | $220.00K | $206.00K | $206.00K | $204.00K | +9.5% |
| Stock-based compensation | $118.00K | $11.00K | $10.00K | $109.00K | $197.00K | +972.7% |
| Change in working capital | -$33.44M | -$579.00K | $435.00K | -$1.51M | $1.08M | -5,675.3% |
| Operating cash flow | -$5.18M | -$5.87M | -$5.29M | -$6.33M | -$5.39M | +11.8% |
| Capital expenditure | -$478.00K | -$2.00K | — | — | — | -23,800.0% |
| Investing cash flow | -$478.00K | -$2.00K | -$104.00K | $0 | $0 | -23,800.0% |
| Financing cash flow | -$2.00K | -$3.00K | -$3.00K | -$209.00K | -$3.00K | +33.3% |
| Free cash flow | -$5.66M | -$5.87M | -$5.39M | -$6.33M | -$5.39M | +3.7% |
| End cash position | $36.81M | $42.47M | $48.33M | $53.72M | $60.26M | -13.3% |
Options analytics
Put / call volume
0.00
Call-heavy session
Put / call open interest
0.00
Positioning, not flow
Max pain
2.50
+129.4% from spot
ATM implied vol
331.3%
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
1
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
2.50
23 contracts
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.20 | 0.89 | +545.0% |
| Mar 2026 | -0.22 | -0.18 | +18.2% |
| Dec 2025 | -0.19 | -0.19 | -1.8% |
| Sep 2025 | -0.32 | -0.16 | +50.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.26 | 2 | $0 | -100.0% |
| Next quarter | -0.23 | 2 | $0 | 0.0% |
| Current year | 0.14 | 2 | $17.50M | +19,344.4% |
| Next year | -0.53 | 2 | $0 | -100.0% |
Analyst targets & ownership
Mean target$3.60
High target$5.00
Low target$2.00
Implied upside230.28%
Analyst count5
ConsensusNONE
Strong buy / Buy1 / 2
Hold1
Sell / Strong sell0 / 0
Held by insiders8.08%
Held by institutions17.31%
Institutions holding56
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.16
-5.63% from price
SMA 20
1.20
-9.13% from price
SMA 50
1.06
+2.77% from price
SMA 100
1.04
+4.48% from price
SMA 200
1.13
-3.92% from price
EMA 12
1.15
-5.48% from price
EMA 26
1.14
-4.66% from price
EMA 50
1.10
-1.32% from price
RSI (14)
44.4
Neutral
MACD (12,26,9)
0.01
Hist -0.02
ATR (14)
0.07
6.22% of price
Realised vol 30D
76.6%
Annualised
Bollinger upper
1.34
20, 2σ
Bollinger lower
1.06
20, 2σ
50 / 200 cross
Death
1.06 vs 1.13
Trend bias
Below 200
-3.92%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.67
Less volatile than market
Correlation to SPY
0.12
Largely independent
Realised vol 30D
76.6%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-55.7%
Peak to trough
Max drawdown 5Y
-94.8%
Peak to trough
ATR 14
0.07
6.22% of price
Beta (reported)
0.27
5Y monthly, from filing
Short interest
Shares short
707.67K
Prior 768.50K
Change vs prior
-7.9%
Shorts covering
% of float
2.26%
Normal
% of shares out
2.25%
Against total outstanding
Days to cover
4.1
Liquid
Float
31.26M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 31, 26 | Stephens & Co. | MAINTAINED | Overweight | Overweight |
| Jun 24, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 12, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 28, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 1, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 27, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 25, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 20, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 18, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 11, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 19, 24 | Stephens & Co. | MAINTAINED | Overweight | Overweight |
| Nov 15, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay dateAug 11, 2020
Last split1:30
Split dateAug 11, 2020
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-14
Periodic Financial Reports
10-Q · 2026-08-07
Corporate Changes & Voting Matters
8-K · 2026-06-18
Corporate Changes & Voting Matters
8-K · 2026-05-29
Periodic Financial Reports
10-Q · 2026-05-08
Periodic Financial Reports
10-K · 2026-03-30
Corporate Changes & Voting Matters
8-K/A · 2026-03-26
Corporate Changes & Voting Matters
8-K · 2026-02-13
Headlines
ATNM: Initiating Coverage – Diversified Nuclear Medicine Portfolio
Zacks Small Cap Research · 22d ago
Actinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference
PR Newswire · 33d ago
Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update
PR Newswire · 54d ago
Actinium: Q2 Earnings Snapshot
Associated Press · 61d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.